LR

Lancet Respiratory Medicine

The Lancet Respiratory Medicine publishes original research contributions that advocate change in or illuminate clinical practice and informative reviews on respiratory medicine and critical care, alongside editorial and commissioned content. Manuscripts are submitted through an online Editorial Manager system, with section-specific requirements, single-anonymised peer review, and options for fast-track review and Online First publication. Open access is offered via gold or subscription green routes for eligible research Articles, with Creative Commons licensing options for gold open access.

Looking to publish in Lancet Respiratory Medicine? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.

Try Livewrite Now
Subject Respiratory System, Critical Care Medicine
Impact Factor 32.8
Quartile Q1
Open Access Type Closed
ISSN 2213-2600
Invitation Only No
Cost Range Manuscript submission is free. Article processing charge (APC) information is provided via the journal’s open access page.

Submission Instructions

Lancet Respiratory Medicine accepts the following article types. Click on an article type to view submission instructions.

Original Article

Cover Letter Cover letter is required for first submissions and must be uploaded at the “Enter Comments” stage in EM. No specific mandatory content elements are specified.
Abstract Abstract is required and must be a semistructured five-paragraph summary (Background, Methods, Findings, Interpretation, Funding) of ≤250 words. For randomised trials, the abstract must follow CONSORT extensions.
Manuscript Main text word limit is up to 3500 words (up to 4500 for randomised controlled trials). Primary research must include a Research in Context panel, and all submitted research Articles must include a data sharing statement.
References Maximum of 30 references. Vancouver numbered style: cite sequentially as superscript numbers after punctuation; list all authors if ≤6, or first 3 then et al if ≥7.
Figures & Tables No maximum number of figures or tables is specified. First submissions must include figures and the manuscript including tables and panels; figures must be supplied as editable files.
Reformat to Lancet Respiratory Medicine using Livewrite Premium

Review Article

Cover Letter A covering letter is required for first submissions and must be uploaded at the “Enter Comments” stage.
Abstract A 150-word unstructured summary is required.
Manuscript Reviews should be 4500 words and must include a brief “Search strategy and selection criteria” section describing sources searched and inclusion/exclusion criteria.
References Maximum 75 references; Vancouver style with superscript numbering in order of appearance (list all authors if ≤6; if ≥7 list first 3 then et al), and do not include references in the Summary or in “Search strategy and selection criteria”.
Figures & Tables Reviews should include about five illustrations/tables/figures; if figures are annotated, supply both an annotated copy and a non-annotated editable copy, and for multi-part figures supply individual parts plus a combined version.
Reformat to Lancet Respiratory Medicine using Livewrite Premium

Meta-analysis

Cover Letter A covering letter is required for first submissions and must be uploaded at the “Enter Comments” stage.
Abstract A structured Summary is required and must not exceed 300 words.
Manuscript Main text must be 3500 words and include a Research in context panel (Evidence before this study; Added value of this study; Implications of all the available evidence).
References References should comprise only studies included in the systematic review or meta-analysis plus up to 30 others. Vancouver numbered superscript citation style is required, cited sequentially after punctuation; list all authors if ≤6, or first 3 then et al if ≥7.
Figures & Tables Include a study-selection flow chart, a table of study characteristics, and a Forest plot with an overall estimate; submit tables in Word and figures as editable files.
Reformat to Lancet Respiratory Medicine using Livewrite Premium

Editorial

Cover Letter Covering letter is required for first submissions and must be uploaded at the “Enter Comments” stage in EM. Revised submissions must include detailed responses to reviewers’ comments in the covering letter.
Abstract Abstract requirement status is not specified. Abstract word limit and structure are not specified.
Manuscript No manuscript word/page limit is specified. Title page must include brief title, author names, one preferred degree, affiliations and full addresses, plus corresponding author contact details (email and telephone).
References No maximum reference count is indicated. References must use Vancouver style, numbered sequentially as superscript after punctuation; list all authors if ≤6, or first 3 then et al if ≥7.
Figures & Tables No maximum number of figures/tables is indicated. Figures/images must be at least 300 dpi (photos also at least 107 mm wide) and previously published images require copyright-holder permission; annotated and multi-part figures need separate files plus a combined version.
Reformat to Lancet Respiratory Medicine using Livewrite Premium

Letter to the Editor

Cover Letter A covering letter is required for first submissions and must be uploaded at the “Enter Comments” stage of online submission.
Abstract Abstract requirement and length/structure are not specified.
Manuscript Letters must respond to content previously published in The Lancet Respiratory Medicine, be submitted within 4 weeks of publication of the original item, and be no longer than 400 words.
References Letters must have no more than 5 references, cited sequentially in Vancouver style as superscript numbers after punctuation; list all authors if ≤6, or first 3 then et al if ≥7.
Figures & Tables Only one table or figure is permitted.
Reformat to Lancet Respiratory Medicine using Livewrite Premium

Recent Publications

Rilzabrutinib and the evolving landscape of oral therapies for uncontrolled asthma

Silvano Dragonieri

10.1016/s2213-2600(26)00001-9
View Publication

Rilzabrutinib for patients with moderate-to-severe asthma with uncontrolled symptoms: a double-blind, placebo-controlled, phase 2 study

Jorge F Maspero, Ian D Pavord, Michael E Wechsler, William Busse, Tanya M Laidlaw, Robert M Mróz, Tian Liu, Vincent Mikol, Benjamin T Suratt, Jessica Gereige, Leda Mannent, Renata Martincova

10.1016/s2213-2600(25)00439-4
View Publication

#Post-tuberculosis lung disease: no ICD code, no problem?

Brian Allwood, Nicola Baines, Ingrid Shoeman, Intan Dewi, Sovannary Tuot, Linda Vat, Rein MGJ Houben

10.1016/s2213-2600(26)00081-0
View Publication

Correction to Lancet Respir Med 2026; published onlineMarch 22. https://doi.org/10.1016/S2213-2600(25)00433-3

-

10.1016/s2213-2600(26)00115-3
View Publication

Russell Winwood: “COPD Athlete” defying views on lung disease

Jackie Duda

10.1016/s2213-2600(26)00084-6
View Publication

Frequently asked questions

How long does it take to publish?

Fast-track Articles are peer-reviewed within 3–5 days and, if accepted, published within 10 weeks from submission. Authors are informed at least a week in advance of the Online First publication date.

Reformat to Lancet Respiratory Medicine using Livewrite Premium

Is a cover letter required?

A covering letter should be uploaded at the “Enter Comments” stage of the online submission process.

Reformat to Lancet Respiratory Medicine using Livewrite Premium

What are the publication costs?

Manuscript submission is free. Gold open access is available for eligible funded research Articles; APC information is provided via the journal’s open access page.

Reformat to Lancet Respiratory Medicine using Livewrite Premium

Research Topics

Chronic Obstructive Pulmonary Disease (COPD) Research Respiratory Support and Mechanisms Asthma and respiratory diseases Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis Neonatal Respiratory Health Research Respiratory and Cough-Related Research COVID-19 Clinical Research Studies Tuberculosis Research and Epidemiology Cystic Fibrosis Research Advances Pneumonia and Respiratory Infections Long-Term Effects of COVID-19 Respiratory viral infections research Intensive Care Unit Cognitive Disorders SARS-CoV-2 and COVID-19 Research Sepsis Diagnosis and Treatment Inhalation and Respiratory Drug Delivery Tracheal and airway disorders Lung Cancer Treatments and Mutations Pulmonary Hypertension Research and Treatments Lung Cancer Diagnosis and Treatment Global Public Health Policies and Epidemiology Influenza Virus Research Studies Climate Change and Health Impacts Air Quality and Health Impacts Smoking Behavior and Cessation

Related Journals

PC
Pediatric Critical Care Medicine LIPPINCOTT WILLIAMS & WILKINS
PA
Pediatric Allergy Immunology And Pulmonology Mary Ann Liebert, Inc.
CC
Critical Care And Resuscitation ELSEVIER
JO
Journal Of The American College Of Cardiology ELSEVIER
JO
Journal Of Thoracic Oncology Elsevier BV
SV
Sarcoidosis Vasculitis And Diffuse Lung Diseases MATTIOLI 1885